Research Suggests Liver Cells are More Susceptible to Cancer

Researchers at the Abramson Cancer Center of the University of Pennsylvania have found that hepatocytes, the chief functional cells of the liver, are at the center of a chain reaction that makes them, and consequently the liver, particularly susceptible to cancer cells.
The researchers found that a previously developed “soil-and-seed hypothesis” largely involve hepatocytes cells. The hepatocytes respond to inflammation by activating a protein called STAT3, which in turn increases their production of other proteins called SAA. These proteins remodel the liver and create the “soil” needed to cancer cells to “seed.” The researchers found that stopping this process by using antibodies that block IL 6—the inflammatory signal that drives this chain reaction—can limit the potential of cancer to spread to the liver.
"The seed-and-soil hypothesis is well-recognized, but our research now shows that hepatocytes are the major orchestrators of this process," said senior author Gregory L. Beatty, MD, PhD.
According to the press release, the investigators used mouse models of pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer and currently the third leading cause of cancer death in the United States. They found that nearly all hepatocytes showed STAT3 activation in mice with cancer, compared with less than 2% of hepatocytes in mice without tumors. The study authors then partnered with investigators at the Mayo Clinic in Arizona and other Penn colleagues to show that this same biology could be seen in patients with pancreatic cancer as well colon and lung cancers.
The investigators found that genetically deleting STAT3 in hepatocytes effectively decreased the liver’s susceptibility to cancer seeding in mice. The team then collaborated with the University of Kentucky to demonstrate that Il-6 controls STAT3 signaling in these cells and instructs hepatocytes to make SAA, which acts as an alarm to attract inflammatory cells and initiate a fibrotic reaction that together establish the “soil.”
According to the study, IL-6 drives changes in the liver whether there's a tumor present or not, implying that any condition associated with increased IL-6 levels—such as obesity or cardiovascular disease—could affect the liver's receptiveness to cancer. The researchers said this provides evidence that therapies targeting hepatocytes may be able to prevent cancer from spreading to the liver, a major cause of cancer mortality.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Top news of the day from across the health care landscape.
Research may lead to potential new targets for preventing cancer in humans.
Ramucirumab (Cyramza, Eli Lilly) is approved as a single agent in patients with elevated alpha fetoprotein who have been previously treated with sorafenib.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.